All News
Might Synovial Biopsy Predict Rheumatoid Treatment Responses?
d
EurekAlert!
Multi-modal analysis of rheumatoid arthritis (RA) synovitis pathotypes enables more accurate choices of first line cDMARDs treatment, suggesting a predictive value to synovial biopsy.
Read Article
Just a reminder - large vessel involvement is very common in GCA, and lines up with aortic dilatation. And if you don’t look, you won’t find…
#EULAR2024 POS0932 @RheumNow https://t.co/2uZTu0B18Z
David Liew drdavidliew ( View Tweet)
Bold conclusion from Japan:
laughter improves function in RA.
I like it
Feel like it might be partially a correlation/causation link but if an hour of laughter can push down IL-6 levels in RA patients, time for reimbursement for stand up comedy?
#EULAR2024 POS1029 @RheumNow https://t.co/EpHnX50PgF
Links:
David Liew drdavidliew ( View Tweet)
Interpreting Hepatis B serology results. Hyrich K #EULAR2024 @RheumNow https://t.co/boXw2XCI2m
Dr. Antoni Chan synovialjoints ( View Tweet)
Approach to TB screening prior
to commencing biologics. Hyrich K #EULAR2024 @RheumNow https://t.co/j3PI0PHpqW
Dr. Antoni Chan synovialjoints ( View Tweet)
New imaging technique PET/CT imaging with 68Gallium-labelled Fibroblast Activation Protein Inhibitor-04 (68Ga-FAPI-04) enables the visualization of fibroblast activation in vivo. No correlations with MSUS findings were found. Fibroblast activation detected by 68Ga-FAPI-04-PET/CT… https://t.co/4VTF1YDzYd https://t.co/Y8Hmlf3sWl
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
Cycle or swap 2? Post failure to a first TNFi in patients with PsA, there was no difference in cycle versus swap to IL17i for drug retention rate or disease activity. In male PsA patients a cycle strategy had a longer drug retention rate compared to a swap (IL-17i) strategy.… https://t.co/5BykvDwFWV https://t.co/GfcnIltV2A
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
Prof Hellmich takes us through “What is new?” In ANCA #vasculitis
A tour de force in management strategies and, continuing a theme of #EULAR2024, ends with a study suggesting the potential of #CAR-T!
@RheumNow https://t.co/K3dDqZhUvD
Mrinalini Dey DrMiniDey ( View Tweet)
What is better for #Rx of
#osteoporosis?
#Denosumab or ##Zoledronic acid?
#Prolia compared to #Aclasta
Giant admin US data of 125,000 Rx niaive women with #OP
▶️Prolia has LESS fractures!
POS0583 #EULAR2024 @eular_org @RheumNow https://t.co/eo1ny2VIRf
Links:
Janet Pope Janetbirdope ( View Tweet)
✨ Delighted to be chairing the session on newly diagnosed #RMDs in the PARE programme this afternoon, featuring a fantastic panel of speakers!
👥 Perfect for patients and clinicians alike!
👇🏼 All details below- hope to see you there
@RheumNow #EULAR2024 https://t.co/8RmcH8qprJ
Links:
Mrinalini Dey DrMiniDey ( View Tweet)
What is better in #PsA
#psoriatic #arthritis
#TNFi or #apremilast #PDE4i
#COREVITAS database study in #PsA
YOU can guess the answer!
1st line advanced RxTNFi lasts longer - retention
Vs PDE4i
#EULAR2024 @RheumNow @eular_org
POS0990 https://t.co/VmYG6Rj87c
Janet Pope Janetbirdope ( View Tweet)
Cycle or Swap? The swap strategy (SG) (i.e. from TNFi to IL17i) had higher retention rates compared to the change strategy (CG) choice in PsA patients who failed the first line of advanced treatment. The 5 years retention rate in SG was higher than in CG (57,8% vs 45,2%; p=0.1).… https://t.co/pH5rFI00vK https://t.co/XqTHO1tIr3
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
Discovery in joint and skin disease - PsA
Three different clusters #EULAR2024 @RheumNow https://t.co/Nj5HZOVqas
Bella Mehta bella_mehta ( View Tweet)
Predicting who will develop
▶️#GCA
In #Swedish study with
#PMR
⬆️ in HIGH ESR/CRP
⬆️female
⬇️ if hip pain/stiffness
Not all sig 1 mo after #prednisone started
Only 9% with #polymyalgia #rheumatica developed #GCA
? ⬇️GCA % in PMR over time
#POS0411 @eular_org @RheumNow https://t.co/UMhxlYd0Pv
Janet Pope Janetbirdope ( View Tweet)
EULAR 2024 Highlights: Friday’s Recap with RheumNow https://t.co/r46kiGalBh
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2024 annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & our faculty.
Dr. John Cush RheumNow ( View Tweet)
The art of talking about risks with our patients
https://t.co/V0JQ1EsbKc https://t.co/GSTbPu0EXZ
Dr. John Cush RheumNow ( View Tweet)
The age old question in #inflammatory #arthritis
Should you cycle within TNFi class or move on to another MOA in
#PsA #psoriatic #arthritis
Better retention to go to a IL17i vs another TNFi in observational study comparing the 2
POS0266
#EULAR2024 @RheumNow @eular_org https://t.co/CXcmYAG4m9
Links:
Janet Pope Janetbirdope ( View Tweet)
Can you predict which pts with
#PsA
#psoriatic #arthritis
Will respond to #TNFi #Rx?
Well, 🤔 maybe
Needs validation and an easy reliable inexpensive biomarker!
#EULAR2024 @RheumNow @eular_org
POS0992 https://t.co/Ce92561AMO
Links:
Janet Pope Janetbirdope ( View Tweet)
Another option for Knee Oa management? Wearable transcutaneous nerve stimulation (W-TENS) reduces the need for surgery. #EULAR2024 @rheumnow abst#POS1072 https://t.co/flcfrCrY2X
Bella Mehta bella_mehta ( View Tweet)